BEAM Alliance, Biotechs of Europe innovating in Anti-Microbial Resistance

Today is #WorldPhageDay Phage therapy brings hope to patients and clinicians faced with #antimicrobialresistance. Innovators are working hard to develop solutions that meet these needs. But there is still a long way to go before phage-based medicinal products are used routinely. BEAM is proud to host the Phage Action Collaborative Taskforce (PACT). BEAM-PACT's mission is to facilitate the development and accessibility of phage-based medicinal products for patients. BEAM-PACT is keen to contribute to the discussion on topics such as regulation, manufacturing, market access, bringing the pragmatic experience of developers. Its main objective is to help supporting guidelines and policies likely to boost the development of phage-based medicinal products. For more information: contact@beam-aliance.eu

Panel discussion at World Health Summit with Florence Sejourne carrying the voice of innovative SMEs! That's during session PD10 "Driving action: innovation and access for a resilient response against antimicrobial resistance / Exploring future scenarios and shaping better solutions". 📆 Oct 14, 14:00-15:30 CET Follow the livestream here 👉https://lnkd.in/ePTKamiN Hosts: CARB-X IFPMA #WHS2024 #AMR #Antibiotics #innovation

The world of biotech is a tough place to make a career in. It is even worse in the #AMR field, where companies struggle raising money and offering a minimal job security. With now only 3000 researchers worldwide, the #antimicrobialresistance R&D workforce has significantly declined over the past 20 years. Action must be taken after this week’s #UNGA2024 to make an AMR innovation career attractive again.

Our Special Envoy at #UNG2024 Remko van Leeuwen is getting ready for the High-Level Meeting on #AMR tomorrow. An important event to deliver an important message. Good luck Remko! #antimicrobialresistance

SMEs are developing 80% of the #antimicrobial pipeline, together with innovative diagnostic approaches. SMEs thus play an instrumental role in identifying solutions to combat the #AMR threat. Its recognition by #UNGA2024 is a great signal sent to our community, whose members are struggling to survive.

Research, Development and Innovation (R&D&I) are key to tackle the threat of #antimicrobialresistance. Recognizing the importance of R&D&I and the need for proper incentive is a strong signal to be sent by the #UNGA2024 later this week. BEAM is working to make the business of #AMR innovation valuable again. We urge policymakers to turn the proposed Political Declaration into concrete actions.

In the real world, no plane would ever take off if it does not know where to land at the end of the journey. In the investment world, people will not invest if there is no reasonable promise of a financial return. In the #antimicrobial field, a #PULLincentive mechanism is the only way to achieve a meaningful financial return for innovators. But - a PULL incentive where the amount would only be known at market entry will never attract developers. Therefore, a subscription mechanism fully based on voluntary contributions from Member States will not work. Guarantees are needed to provide enough predictability for innovators to truly incentivise research and development. See our further thoughts in our latest reflection paper 👉 https://lnkd.in/efBKhmSZ   #AMR #antimicrobialresistance

We look forward to meeting up with the entire AMR innovation community to share the latest news and trends in the field! https://lnkd.in/eSDCVsER AMR Conference #antimicrobialresistance #AMR

Between €1billion and €1.5billion. That’s - on average - the range of income an antimicrobial should make over 10 years in the EU27 to fairly reimburse the effort, cost and risk taken during development. This money should delink the volume of use from revenue ensuring best stewardship and thus preserve the drug efficacy as best as it can.   Is this a lot? No. And with this amount of revenue, such an antimicrobial would not rank in the world’s top 200 drugs, even though it would bring huge societal benefits. Is this figure only supported by industry? No. Much independent research supports this figure. Besides, the UK just launched its own subscription mechanism, offering up to £23.7million per year for a new antimicrobial. If applied to EU27 (pro rata GDP), the mechanism would deliver up to €1.5 billion over 10 years. Exactly what is needed. Said differently, the UK has shown leadership in changing the fate on one of humankinds’ biggest health challenges. The target is known. We call on EU policymakers to use the UK's experience in setting up the long-awaited PULL mechanism. To find out more 👉 https://lnkd.in/efBKhmSZ  

 📢 Breaking News: Parliamentary Group Against AMR Formed in Germany!  On June 13, 2024, members of the German Parliament (Bundestag) from some of the country’s major political parties convened and formed a parliamentary group dedicated to combating antimicrobial resistance (AMR). 🦠 AMR poses a significant global health threat, causing millions of deaths annually, including 35,000 in the EU alone. The establishment of this specialized group demonstrates Germany’s commitment to tackling this global crisis! Members of the Parliamentary Group include: Alliance 90/The Greens: Johannes Wagner CDU/CSU: Stephan Albani, Prof. Dr. Helge Braun, Hermann Gröhe, Dr. Georg Kippels, Katrin Staffler The Left: Dr. Petra Sitte FDP: Kristine Lütke, Prof. Dr. Andrew Ullmann SPD: Dr. Holger Becker, Dr. Franziska Kersten, Tina Rudolph 🎉 @BEAM Alliance welcomes the formation of this cross-party Parliamentary Group. We are confident that with unified support from parliamentarians across party lines, the fight against AMR will gain significant momentum and will also adress the need of SMEs! SMEs need establishing working pull incentive mechanisms in order to help tackle market failures for antimicrobials. We also extend our congratulations to Dr. Georg Kippels on being elected as the group's spokesperson, and to Dr. Franziska Kersten on being elected as deputy chair. We strongly believe that their leadership will be instrumental in driving efforts forward. 👍Timo Jaeger, spokesperson for the German Network against AMR (DNAMR) and Managing Director of German Center for Infection Research – a close and valuable partner of the Hub – also shares this view: “We are pleased to have specific contacts in the parliamentary group to discuss suitable measures and advocate for them with the political support of the federal government.” @Beam Alliance, as a founding member of the DNAMR, is eager to support and collaborate with the group in the fight against AMR. Together, we can drive sustainable research and innovation and safeguard public health.  👉 Find out more here (in German): https://lnkd.in/eRXcQ3Mm #ParliamentaryGroupAgainstAMR #AntimicrobialResistance #GlobalHealth #Germany #GlobalAMRHub Photos: @TillmannKonrad/DNAMR